On November 1, 2018 Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) reported that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), will be presented during an oral session at the 2018 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, December 1-4, 2018 in San Diego, California (Press release, Portola Pharmaceuticals, NOV 1, 2018, View Source;p=RssLanding&cat=news&id=2374918 [SID1234530526]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also will present new outcomes-based research on the burden of hospital readmissions for venous thromboembolism among patients with cancer during an oral session on Sunday, December 2, and two investigator-initiated animal studies highlighting the anticoagulant reversal agent Andexxa [coagulation Factor Xa (recombinant), inactivated-zhzo] will be presented in poster sessions.

"As shown at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and European Hematology Association (EHA) (Free EHA Whitepaper) meetings earlier this year, cerdulatinib has shown encouraging results across a range of B- and T-cell malignancies and we look forward to presenting new data specifically focused on patients with PTCL and CTCL," said John Curnutte, M.D., Ph.D., head of research and development for Portola. "These data also will serve as a basis for further discussions with regulatory agencies regarding the potential regulatory path forward for cerdulatinib in certain tumor subtypes."

Cerdulatinib is an investigational oral, dual Syk/JAK kinase inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. It is being developed for the treatment of resistant or relapsed hematologic cancer.

Oral Presentations

1001. The Novel Syk/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Abstract: View Source
Session: 624 (Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T Cell Lymphoma: Chemotherapy and Targeted Approaches)
Presenter: Steven M. Horwitz, M.D., Memorial Sloan-Kettering Cancer Center
Date: Monday, December 3, 2018 at 7:15 p.m. PST; Room 6F

365. Burden of Hospital Readmissions for Venous Thromboembolism Among Patients with Cancer
Abstract: View Source
Session: 901 (Health Services Research—Non-Malignant Conditions: Thrombosis and Anticoagulation
Hematology Disease Topics & Pathways)
Presenter: Alpesh Amin, M.D., M.B.A., UC Irvine
Date: Sunday, December 2, 2018 at 10:30 a.m. PST; Room 8
Poster Presentations

2456. Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model
Abstract: View Source
Session: 321 (Blood Coagulation and Fibrinolytic Factors: Poster II Hematology Disease Topics & Pathways)
Presenter: Oliver Grottke, M.D., Ph.D., M.P.H., University Hospital RWTH Aachen, Germany
Date: Sunday, December 2, 2018 from 6:00 – 8:00 p.m. PST; Hall GH

3778. Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation
Abstract: View Source
Session: 321 (Blood Coagulation and Fibrinolytic Factors: Poster II Hematology Disease Topics & Pathways)
Presenter: Oliver Grottke, M.D., Ph.D., M.P.H., University Hospital RWTH Aachen, Germany
Date: Monday, December 3, 2018 from 6:00 – 8:00 p.m. PST; Hall GH